Bicycle Therapeutics plc
BCYC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,734 | $2,920 | $9,977 | $3,708 |
| % Growth | 301.8% | -70.7% | 169.1% | – |
| Cost of Goods Sold | $0 | $71,029 | $57,271 | $56,072 |
| Gross Profit | $11,734 | -$68,109 | -$47,294 | -$52,364 |
| % Margin | 100% | -2,332.5% | -474% | -1,412.2% |
| R&D Expenses | $58,426 | $71,029 | $59,058 | $49,778 |
| G&A Expenses | $19,017 | $19,238 | $21,123 | $21,021 |
| SG&A Expenses | $19,017 | $19,238 | $20,924 | $21,021 |
| Sales & Mktg Exp. | $0 | $0 | -$199 | $0 |
| Other Operating Expenses | -$158 | -$71,774 | -$57,072 | -$55,500 |
| Operating Expenses | $77,285 | $18,493 | $22,910 | $15,299 |
| Operating Income | -$65,551 | -$86,602 | -$70,204 | -$67,663 |
| % Margin | -558.6% | -2,965.8% | -703.7% | -1,824.8% |
| Other Income/Exp. Net | $6,656 | $7,419 | $8,363 | $14,712 |
| Pre-Tax Income | -$58,895 | -$79,183 | -$61,841 | -$52,951 |
| Tax Expense | $205 | -$231 | -$1,087 | -$1,082 |
| Net Income | -$59,100 | -$78,952 | -$60,754 | -$51,854 |
| % Margin | -503.7% | -2,703.8% | -608.9% | -1,398.4% |
| EPS | -0.85 | -1.14 | -0.88 | -0.74 |
| % Growth | 25.4% | -29.5% | -18.9% | – |
| EPS Diluted | -0.85 | -1.14 | -0.88 | -0.74 |
| Weighted Avg Shares Out | 69,304 | 69,252 | 69,197 | 69,052 |
| Weighted Avg Shares Out Dil | 69,304 | 69,252 | 69,197 | 69,052 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $7,473 | $8,414 | $10,303 |
| Interest Expense | $44 | $54 | $51 | $52 |
| Depreciation & Amortization | $1,756 | $1,696 | -$8,312 | $1,704 |
| EBITDA | -$57,095 | -$77,433 | -$70,204 | -$65,959 |
| % Margin | -486.6% | -2,651.8% | -703.7% | -1,778.8% |